GlaxoSmithKline - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: GlaxoSmithKline announced a $2.36 billion charge to second-quarter earnings, to cover the cost of resolving several legal problems including the Avandia settlement, but also a $750 million deal to dispose of a U.S. manufacturing investigation.


  • Q2 sales £7.0 billion (level); progress in diversification strategy offsets US decline.
  • H1 total sales £14.4 billion (+7%); sales excluding pandemic products +1%
  • Sustained pipeline delivery and development of portfolio.
  • Ongoing efforts to resolve long-standing legal cases; pre-announced Q2 legal charge of £1.57 billion
  • Continued focus on cost control and strong cash generation.

See GSK's current stock quote from CNN Money

GSK's website:
Full release: GSK's earnings release

GlaxoSmithKline - Big Pharma's Q2 2010 Earnings Report

Suggested Articles

Drug pricing remains the pharma industry's top concern in 2020, execs said in a survey, as political threats continue from Washington, D.C.

Allergan updated its Botox marketing for chronic migraine by featuring strong women powering through their too-frequent migraine days.

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.